Allos
allos.com
Actively hiring
Drug Discovery
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$5M
1 round on record
Latest round
$5M
Venture round · Jan 2026 · 8 mo ago
Team
51-200
employees, estimated range
Backers
2
Oak Investment Partners, Oxford Science Enterprises
The money's age
Fresh money
8 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 12
Raised a round Venture round $5M · Pulse 2.0
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jan 2026 | $5M | — | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Oak Investment Partners 
Oxford Science Enterprises Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Accelerate intelligent drug development with DVLP. We harness collaborative AI to move molecules to commercialized intelligent drugs with…
ABOUT US IteriaBiopharma is a privately owned Spanish biotech founded in 2024 by a team of experienced entrepreneurs in drug discovery and…
AI-first biotech accelerating early drug discovery with protein–ligand insights and advanced models for molecular understanding. Khumbu.ai.
Abinitio bio is the AI-native operating platform for drug development and manufacturing.
Babylon is a drug development company pursuing a transformational treatment for Alzheimer’s. Meet our team and explore how we discover…
Bio is building science for the network age, connecting biotech funding, AI research, and distribution across the bio.xyz ecosystem.
Overview
Allos uses causal AI to model drug formulation before experimentation, cutting spend, timelines, and risk for pharmaceutical and biotech development teams.
News
ALLOS ON ED NM (ALOS3.SA) Q1 FY2026 earnings call transcript
Read ALLOS ON ED NM (ALOS3.SA) Q1 FY2026 earnings call transcript on Yahoo Finance to keep your investing strategy up to date with all of the latest information
Read more
Report
Report
Allos Raises $5M to Apply Causal AI Across Complex Drug Reformulation
The post Allos Raises $5M to Apply Causal AI Across Complex Drug Reformulation appeared first on Allos.
Read more
Report
Allos: $5 Million Raised To Apply Causal AI Across Complex Drug Reformulation
Allos AI has raised $5 million in seed financing to commercialize what it calls the industry's first
Read more
Report
Allos Pharma Acquires Global Rights to Arbaclofen, Reports Positive ASD Trial Results and Grant Award
Allos Pharma Inc., announces key milestones advancing its mission to deliver effective treatments for Autism Spectrum Disorder (ASD), Fragile X Syndrome, and related neurodevelopmental disorders.
Read more
Report
Allos Pharma secures exclusive license on arbaclofen in Fragile X Syndrome
/PRNewswire/ -- Allos Pharma Inc, a late-stage pharmaceutical company developing therapeutics for neurodevelopmental disorders, has announced the exclusive...
Read more
Report
Allos Ventures: New $52 Million Fund Closed To Invest In Early-Stage Startups
Allos Ventures is a Midwest-based firm that recently closed a $52 million fund called Allos III. These are the details about the new fund.
Read more
Report
Report
Show more news
Financials
Total raised
$5M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $5M | Details |